Globeflex Capital’s Keros Therapeutics KROS Stock Holding History

Globeflex Capital’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-37,873	Closed	-$418K	–	428
2026 Q1	$418K	Buy	+37,873	New	+$585K	0.06%	242

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Globeflex Capital's KROS Position: Q2 2026 in Review

Globeflex Capital sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 37,873 shares — an estimated $418K sold.

Globeflex Capital first reported a position in KROS in Q1 2026 and held it in 1 quarter. The position peaked at $418K in Q1 2026. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

Globeflex Capital reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
Globeflex Capital sold 37,873 Keros Therapeutics shares in Q2 2026, an estimated $418K.
Globeflex Capital first reported a position in Keros Therapeutics in Q1 2026 and held it in 1 quarter.
Globeflex Capital's Keros Therapeutics position peaked at $418K in Q1 2026.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Globeflex Capital's 13F filing for Q2 2026, filed 12 Aug 2026.